Landogrozumab
Landogrozumab (INN; development code LY2495655) is a humanized monoclonal antibody and experimental pharmaceutical drug designed for the treatment of muscle wasting disorders.[1][2]
Monoclonal antibody | |
---|---|
Type | Whole antibody |
Source | Humanized (from mouse) |
Target | GDF-8 |
Clinical data | |
Other names | LY2495655 |
ATC code |
|
Identifiers | |
CAS Number | |
ChemSpider |
|
UNII | |
KEGG | |
Chemical and physical data | |
Formula | C6338H9790N1694O1988S42 |
Molar mass | 142874.43 g·mol−1 |
This drug was developed by Eli Lilly & Co.
References
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.